2型糖尿病治疗方案对糖尿病困扰和抑郁症状的差异效应:GRADE研究
GRADE研究纳入病程<10年、HbA1c 6.8-8.5%、单用二甲双胍的2型糖尿病成人,随机加用甘精胰岛素U-100、格列美脲、利拉鲁肽或西格列汀。情绪困扰亚组纳入1739例,每6个月评估糖尿病困扰和抑郁症状。1年时甘精胰岛素组糖尿病困扰低于其他组联合,利拉鲁肽组低于格列美脲或西格列汀组;3年随访总糖尿病困扰无显著组间差异,抑郁症状无显著差异。
要点
- 1年时甘精胰岛素组糖尿病困扰低于其他组联合(-0.10,P=0.002)。
- 利拉鲁肽组1年糖尿病困扰低于格列美脲或西格列汀组(-0.10,P=0.008)。
- 3年随访总糖尿病困扰及抑郁症状无显著组间差异。
核心结论
- 与预期相反,该随机试验未发现基础胰岛素对情绪困扰有不良影响的证据。
- 甘精胰岛素在1年时轻度降低而非增加糖尿病困扰,利拉鲁肽也降低1年糖尿病困扰。
- 结果可为早期2型糖尿病成人的治疗决策提供信息。
研究设计与样本
- GRADE研究为随机对照试验,纳入病程<10年、HbA1c 6.8-8.5%、单用二甲双胍的2型糖尿病成人,随机加用甘精胰岛素U-100、格列美脲、利拉鲁肽或西格列汀。
- 情绪困扰亚组纳入1739例GRADE参与者,平均(SD)年龄58.0(10.2)岁,32%女性,56%非西班牙裔白人,18%非西班牙裔黑人,17%西班牙裔。
- 每6个月评估糖尿病困扰和抑郁症状,分析比较1年时及3年随访期间的差异。
主要发现
- 1年期间所有治疗组糖尿病困扰(-0.24,P<0.0001)和抑郁症状(-0.67,P<0.0001)均下降。
- 1年时甘精胰岛素组糖尿病困扰低于其他组联合(-0.10,P=0.002)。
- 利拉鲁肽组糖尿病困扰低于格列美脲或西格列汀组(-0.10,P=0.008)。
- 3年随访期间总糖尿病困扰无显著组间差异,人际糖尿病困扰在利拉鲁肽组仍较低。
- 抑郁症状未观察到显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated whether adding basal insulin to metformin in adults with early type 2 diabetes mellitus (T2DM) would increase emotional distress relative to other treatments. RESEARCH DESIGN AND METHODS: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) of adults with T2DM of <10 years' duration, HbA1c 6.8-8.5%, and taking metformin monotherapy randomly assigned participants to add insulin glargine U-100, sulfonylurea glimepiride, the glucagon-like peptide-1 receptor agonist liraglutide, or the dipeptidyl peptidase 4 inhibitor sitagliptin. The Emotional Distress Substudy enrolled 1,739 GRADE participants (mean [SD] age 58.0 [10.2] years, 32% female, 56% non-Hispanic White, 18% non-Hispanic Black, 17% Hispanic) and assessed diabetes distress and depressive symptoms every 6 months. Analyses examined differences at 1 year and over the 3-year follow-up. RESULTS: Across treatments, diabetes distress (-0.24, P < 0.0001) and depressive symptoms (-0.67, P < 0.0001) decreased over 1 year. Diabetes distress was lower at 1 year for the glargine group than for the other groups combined (-0.10, P = 0.002). Diabetes distress was also lower for liraglutide than for glimepiride or sitagliptin (-0.10, P = 0.008). Over the 3-year follow-up, there were no significant group differences in total diabetes distress; interpersonal diabetes distress remained lower for those assigned to liraglutide. No significant differences were observed for depressive symptoms. CONCLUSIONS: Contrary to expectations, this randomized trial found no evidence for a deleterious effect of basal insulin on emotional distress. Glargine lowered diabetes distress modestly at 1 year rather than increasing it. Liraglutide also reduced diabetes distress at 1 year. Results can inform treatment decisions for adults with early T2DM.
引用
- Gonzalez JS, Bebu I, Krause-Steinrauf H, et al. Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2024. PMID: 38416773. doi:10.2337/dc23-2459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。